BioCardia (BCDA) Competitors

Actinium Pharmaceuticals (NYSE:ATNM) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends.

Is ATNM or BCDA more profitable?

Actinium Pharmaceuticals has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. BioCardia's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
BioCardia	-1,999.77%	N/A	-208.38%

Do insiders and institutionals hold more shares of ATNM or BCDA?

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 6.0% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 20.0% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has preferable earnings & valuation, ATNM or BCDA?

BioCardia has lower revenue, but higher earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$81K	697.10	-$48.82M	-$1.39	-1.30
BioCardia	$58K	225.93	-$11.57M	-$3.09	-0.91

Which has more volatility and risk, ATNM or BCDA?

Actinium Pharmaceuticals has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

Do analysts recommend ATNM or BCDA?

Actinium Pharmaceuticals presently has a consensus target price of $7.40, indicating a potential upside of 308.84%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 792.86%. Given BioCardia's stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
BioCardia	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Does the media refer more to ATNM or BCDA?

In the previous week, Actinium Pharmaceuticals had 23 more articles in the media than BioCardia. MarketBeat recorded 28 mentions for Actinium Pharmaceuticals and 5 mentions for BioCardia. BioCardia's average media sentiment score of 0.55 beat Actinium Pharmaceuticals' score of 0.33 indicating that BioCardia is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCardia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer ATNM or BCDA?

BioCardia received 9 more outperform votes than Actinium Pharmaceuticals when rated by MarketBeat users. Likewise, 60.71% of users gave BioCardia an outperform vote while only 50.00% of users gave Actinium Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Actinium Pharmaceuticals	Outperform Votes 8 50.00%	Underperform Votes 8 50.00%
BioCardia	Outperform Votes 17 60.71%	Underperform Votes 11 39.29%

Summary

BioCardia beats Actinium Pharmaceuticals on 11 of the 19 factors compared between the two stocks.